Corinne Johnson
Stock Analyst at Goldman Sachs
(2.51)
# 2,189
Out of 4,993 analysts
14
Total ratings
46.15%
Success rate
6.08%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Corinne Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMLX Amylyx Pharmaceuticals | Maintains: Buy | $10 → $20 | $13.82 | +44.72% | 2 | Sep 16, 2025 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $20 → $24 | $15.03 | +59.68% | 2 | Sep 5, 2025 | |
| RNA Avidity Biosciences | Reinstates: Buy | $55 | $40.84 | +34.67% | 2 | Jul 10, 2025 | |
| AVBP ArriVent BioPharma | Reinstates: Buy | $33 | $17.17 | +92.20% | 3 | Jul 10, 2025 | |
| NBIX Neurocrine Biosciences | Initiates: Buy | $182 | $140.89 | +29.18% | 1 | Jul 10, 2025 | |
| CGON CG Oncology | Upgrades: Buy | $43 → $50 | $36.48 | +37.06% | 3 | May 14, 2024 | |
| IMVT Immunovant | Initiates: Buy | $50 | $15.67 | +219.08% | 1 | Mar 13, 2024 |
Amylyx Pharmaceuticals
Sep 16, 2025
Maintains: Buy
Price Target: $10 → $20
Current: $13.82
Upside: +44.72%
Syndax Pharmaceuticals
Sep 5, 2025
Maintains: Buy
Price Target: $20 → $24
Current: $15.03
Upside: +59.68%
Avidity Biosciences
Jul 10, 2025
Reinstates: Buy
Price Target: $55
Current: $40.84
Upside: +34.67%
ArriVent BioPharma
Jul 10, 2025
Reinstates: Buy
Price Target: $33
Current: $17.17
Upside: +92.20%
Neurocrine Biosciences
Jul 10, 2025
Initiates: Buy
Price Target: $182
Current: $140.89
Upside: +29.18%
CG Oncology
May 14, 2024
Upgrades: Buy
Price Target: $43 → $50
Current: $36.48
Upside: +37.06%
Immunovant
Mar 13, 2024
Initiates: Buy
Price Target: $50
Current: $15.67
Upside: +219.08%